Uncategorized

Lilly climbs, Novo falls as obesity drug battle intensifies

A research disappointment and a miss on Wegovy pill sales hurt Novo, while Lilly’s injectable franchise once again surpassed analyst expectations.

Published

1 day ago

on

August 5, 2026

By

Temp User

A research disappointment and a miss on Wegovy pill sales hurt Novo, while Lilly’s injectable franchise once again surpassed analyst expectations.

Related Topics:

Leave a Reply

Fierce Biotech4 months ago

Scientists turn pig semen extract into eye drops that kill cancer in mice
Uncategorized9 years ago

These ’90s fashion trends are making a comeback in 2017
Endpoints News5 months ago

Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
Uncategorized5 months ago

Novartis buys Synnovation’s PI3Kα inhibitors for $3 billion
Uncategorized9 years ago

According to Dior Couture, this taboo fashion accessory is back
Uncategorized9 years ago

Steph Curry finally got the contract he deserves from the Warriors

Exit mobile version